Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4454-4463

  Bartalena, Luigi ^a   Krassas, G E ^b   Wiersinga, W ^c   Marcocci, C ^d   Salvi, M ^e   Daumerie, C ^f   Bournaud, C ^g   Stahl, M ^g   Sassi, L ^a   Veronesi, G ^a   Azzolini, C ^a   Boboridis, K G ^j   Mourits, M P ^c   Soeters, M R ^c   Baldeschi, L ^c   Nardi, M ^d   Curro N ^k   Boschi, A ^f   Bernard, M ^h   Von Arx, G ⁱ  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b PANAGIA GENERAL HOSPITAL   (Greece)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PISA   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g Fondazione IRCCS Ca' Granda ^*  (Switzerland)

^h UNIVERSITÉ LYON 1   (France)

ⁱ Admedico Augenzentrum Olten   (Switzerland)

^j AHEPA UNIVERSITY HOSPITAL   (Greece)

^k NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ACTIVITY SCORE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIPLOPIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; ORBIT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870764713     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2389     Document Type: Article

References (34)

1. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738
2. Smith TJ 2010 Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest 33:414-421
3. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves'ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199
4. Wiersinga WM 2010 Quality of life. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy-a multidisciplinary approach, questions and answers. 2nd revised edition. Basel, Switzerland: Karger; 211-220
5. Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B 2009 The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol 161:483-487
6. Baldeschi L 2010 Rehabilitative surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy-a multidisciplinary approach, questions and answers. 2nd revised edition. Basel, Switzerland: Karger; 167-170
7. Hegedus L, Smith TJ, Douglas RS, Nielsen CH 2011 Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with rituximab. Clin Endocrinol (Oxf) 74:1-8
8. Bartalena L 2010 What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 73:149-152
9. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx C, Wiersinga WM 2008 Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 18:333-346 (Pubitemid 351415802)
10. Zang S, Kahaly GJ 2011 Steroids and immune response in Graves'orbitopathy. Immun Endoc Metab Agents Med Chem 11:90-98
11. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri A, Cartei F, Nardi M, Pinchera A 2001 Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86:3562-3567 (Pubitemid 32755944)
12. Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves'orbitopathy. J Clin Endocrinol Metab 90:5234-5240 (Pubitemid 41262280)
13. Stiebel-Kadish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L 2009 Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 94:2708-2716
14. Bahn RS 2012 High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now? Thyroid 22:1-2
15. Dickinson AJ, Perros P 2001 Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55:283-303 (Pubitemid 32823038)
16. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47:9-14 (Pubitemid 27313981)
17. Bahn RS, Gorman C 1987 Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin N Am 16:391-407 (Pubitemid 18088083)
18. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, Prummel MF, Wiersinga WM 2001 Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QoL) after different treatments. Clin Endocrinol (Oxf) 54:391-398 (Pubitemid 32234205)
19. Bartalena L, Tanda ML 2009 Clinical practice-Graves' ophthalmopathy. N Engl J Med 360:994-1001
20. Bartalena L 2012 Prevention of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:371-379
21. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel MF, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga WM, for the European Group on Graves' Orbitopathy 2011 Selenium and the course of mild Graves' orbitopathy. N Engl J Med 364:1920-1931
22. Zang S, Ponto KA, Kahaly GJ 2011 Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320-332
23. Zang S, Ponto KA, Pitz S, Kahaly GJ 2011 Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J Endocrinol Invest 34:880-884
24. Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J, Bartalena L, for the European Group on Graves'Orbitopathy 2012 Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 166:247-253
25. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L, Pinchera A 1983 Orbital cobal irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56:1139-1144 (Pubitemid 13055106)
26. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A 1991 Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 14:853-860
27. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C 2004 Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves'ophthalmopathy. Thyroid 14:403-406 (Pubitemid 38756663)
28. Lerndorf ME, Rasmussen AK, Fledelius HC, Feldt-Rasmussen U 2009 Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid 19:1431-1432
29. Owecki M, Sowiński J 2006 Acute myocardial infarction during-high-dose methylprednisolone therapy for Graves' ophthalmopathy. Pharm World Sci 28:73-75 (Pubitemid 44510950)
30. Gursoy A, Cesur M, Erdogan MF, Corapcioglu D, Kamel N 2006 New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 29:513-516 (Pubitemid 44358842)
31. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM 2007 Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17:357-362 (Pubitemid 46776141)
32. Wichary H, Gasińska T 2012 Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy. Thyroid 22:64-69
33. Laurberg P, Berman DC, Bülow Pedersen I, Andersen S, Carlé A 2012 Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325-2332
34. Steyerberg EW, Bossuyt PM, Lee KL 2000 Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J 139:745-751 (Pubitemid 30305391)